← All articles

Muscle Preservation During GLP-1 Weight Loss: Research Beyond the Scale

Bookmark this page

Save this article in your browser so you can find it again:

  • Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
  • iPhone or iPad: In Safari, tap Share, then Add Bookmark.
  • Android: In Chrome, open the menu and tap the star.

Other browsers may use a different menu.

Can exercise or an additional treatment preserve muscle and physical function during GLP-1-based weight loss? Human trials are beginning to answer parts of that question. A November 2026 tirzepatide study measured both lean tissue and strength, adding direct exercise evidence to the research discussed below. A smaller decline in lean mass on a scan still does not automatically mean better mobility or a favorable overall benefit-risk balance.

Bio Peptides Labs would like future studies to answer the functional question as carefully as the body-composition question. This is our editorial research agenda, not a claim that we are running these trials or offering a validated combination.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. Selected original publications, indexed abstracts and official sources were checked on November 13, 2026. Some full reports were inaccessible; the evidence reviewed is not an exhaustive systematic review. This article describes research, not a treatment plan or a recommendation to use catalog materials personally.

A proposed muscle-preservation research framework combines tissue measurements, physical function and safety outcomes rather than relying on body weight alone.
Our proposed reading framework for GLP-1 adjunct studies. It is not trial data or a validated scoring system, and it does not endorse any personal-use combination.

Lean mass, skeletal muscle and function answer different questions

DXA divides body composition into categories including fat and lean soft tissue. Lean mass is not exclusively skeletal muscle, and its change is not a direct measurement of strength. Muscle imaging can help localize tissue changes, but performance still needs its own assessment.

That distinction is visible in a clinical trial of the nonpeptide ghrelin mimetic ibutamoren, also called MK-677. Older adults gained fat-free mass without demonstrated improvement in strength or function; glucose regulation also worsened. The study did not involve GLP-1 treatment. It illustrates why a favorable body-composition marker is an incomplete answer. Original randomized trial.

Our proposed outcome hierarchy would be:

Research evidence map

Measurement

What it helps answer

What remains unresolved

Body weight

Did total weight change?

Which tissues changed, and did health or function improve?

DXA lean and fat mass

How did measured body compartments change?

Was skeletal muscle function preserved?

Muscle imaging

Did a defined muscle region change in size or composition?

Did strength and daily performance improve?

Strength and performance tests

Did measured physical abilities change?

Was the improvement meaningful and durable for participants?

Daily function and safety

Did participants experience useful benefit with acceptable harms?

How does it hold up over longer follow-up and in other populations?

This is a proposed framework for interpreting studies, not a scoring system validated by Bio Peptides Labs.

Tirzepatide and resistance training: a November 2026 randomized trial

A study published November 9 followed 120 participants who entered a randomized trial comparing tirzepatide with supervised resistance training against tirzepatide with usual activities for 40 weeks. Average weight and fat reductions were similar, but the exercise group lost less lean soft tissue and improved the tested strength measures. Original study abstract.

Research evidence map

Outcome

Tirzepatide with usual activities

Tirzepatide with resistance training

Average lean soft tissue change

−4.67 kg

−3.57 kg

Tested upper- and lower-body strength

Decreased

Increased

Weight and fat changes

Similar reductions between groups

Similar reductions between groups

The modeled between-group lean-tissue difference was 1.09 kg, with reported interval bounds of 0.43–1.75 kg. The paper’s abstract labels these bounds a 95% confidence interval, while its results and methods label them 97.5%; we cannot resolve that inconsistency from the report. Lean-tissue loss was reduced, not eliminated. Gastrointestinal symptoms occurred in both groups; six participants withdrew because of adverse events. Original report.

The prospective registry specifies men and postmenopausal women aged 50–70, with low prior activity, and exclusions including diabetes and cardiovascular disease. This was a selected population and supervised program. It cannot establish the same outcome for every age, exercise routine or incretin drug. Prospective trial record.

For this November 16 update, the indexed original abstract, indexed publisher results/methods and prospective registry were checked. Direct full-publisher access failed; the supplement and individual data were not independently reviewed. Earlier antibody and catalog-adjunct source checks below retain their November 13 scope.

This study strengthens the case for measuring function alongside body composition. It does not test a research-peptide stack or establish an exercise prescription for an individual.

Three human combination trials worth reading carefully

These studies tested monoclonal antibody adjuncts with incretin medicines. They did not test the small research peptides commonly sold as “stacks.” Their results cannot be transferred to a different substance, formulation or incretin drug.

BELIEVE: bimagrumab with semaglutide

The 507-participant BELIEVE trial reported less total lean-mass loss in combination groups than with semaglutide alone. Bimagrumab targets activin receptors. The paper did not demonstrate a significant grip-strength improvement; questionnaire findings varied by measure and group. Muscle spasms, diarrhea and acne were among adverse effects associated with bimagrumab; semaglutide treatment was open-label during the primary period. Original BELIEVE publication.

EMBRAZE: apitegromab with tirzepatide

EMBRAZE randomized 102 adults for 24 weeks. Its treatment-completer analysis found less DXA lean-mass loss with the combination, but no notable between-group physical-function differences. The reported uncertainty interval was 80%, and statistical comparisons were descriptive without adjustment for multiple comparisons. Apitegromab inhibits activation of precursor myostatin. The small, short study leaves long-term function and safety questions open. Original EMBRAZE publication.

COURAGE: trevogrumab with semaglutide, with or without garetosmab

The newly published COURAGE trial found less lean-mass loss in some trevogrumab combination arms; functional benefit still needed investigation. The triple combination adding garetosmab had unfavorable safety and tolerability, including frequent muscle spasms and discontinuations. Two deaths occurred in that arm, without an identified causal association. This is a concrete reason to test harms rather than assume that adding another mechanism improves a combination. Original COURAGE publication.

All three were industry-associated development studies. These summaries emphasize selected findings and limits; they are not head-to-head comparisons or recommendations for clinical use.

What about retatrutide and muscle loss?

A retatrutide body-composition substudy involved adults with type 2 diabetes. Of 189 enrolled, 103 completed treatment and had baseline and week-36 DXA scans. Its primary body-composition endpoint concerned fat mass. The authors reported that the proportion of weight loss coming from lean mass was similar to other obesity treatments. That does not mean no muscle was lost or that strength was protected. Original retatrutide substudy.

The population, missing follow-up measurements and endpoints limit what can be generalized. The study did not test any adjunct described above. Retatrutide also remains investigational and not FDA approved as of this review. FDA information.

The research priorities we would put first

We would like qualified investigators to test an adjunct's added value against a meaningful comparator, with the same background support in both groups. An exercise-plus-liraglutide randomized trial provides a separate example of studying a combined approach to weight-loss maintenance. It does not validate a retatrutide or research-peptide combination. Original exercise and liraglutide trial.

For future adjunct trials, our priorities are:

  1. Function alongside tissue measurements. Prespecify strength, chair-rise or walking performance and daily-life outcomes, with meaningful change thresholds rather than relying only on statistical significance.

  2. People at different baseline risk. Examine whether findings differ by age, sex, diabetes status or low baseline muscle mass. Subgroup analyses need adequate planning and sample size.

  3. Comparable background care. Record nutrition and activity support consistently, so an apparent drug effect is not simply a difference in the care groups received.

  4. The actual combination. Test the specific agent with the specific background medicine. A semaglutide result cannot establish a retatrutide result.

  5. Longer observation. Examine weight stabilization, treatment withdrawal and weight regain, alongside durability of any functional effect.

  6. A complete account of harms. Include glucose regulation, fluid retention, cardiovascular events, tolerability, withdrawals and serious adverse events as appropriate to the investigational agents.

These are proposed questions for formal, ethically reviewed research. They do not specify a dose, regimen or self-experimentation method.

Do CJC-1295, ipamorelin or MOTS-c already answer this question?

In the targeted primary-source and registry searches we reviewed on November 13, 2026, we did not identify controlled human evidence that the listed catalog-style adjuncts preserve muscle or function during GLP-1 treatment. The search included CJC-1295, ipamorelin, ibutamoren/MK-677, MOTS-c, elamipretide/SS-31, BPC-157 and TB-500 with named incretin drugs or GLP-1 terms. This bounded search is not proof that no study exists.

Hormone responses, exercise-related biomarkers or animal results address different questions. Our retatrutide combination-research guide explains those gaps and why chemical identity matters. For the separate skin question, read GHK-Cu and loose skin after GLP-1 weight loss.

Questions readers ask

Can a study preserve lean mass without improving strength?

Yes. Tissue measurements and physical performance are different endpoints, and the reviewed trials show why both need to be reported. A trial can also be too small or too short to settle a functional question.

Did resistance training prevent all lean-tissue loss?

No. Both groups lost lean soft tissue in the reviewed trial, although the exercise group lost less and improved measured strength. This distinction helps keep body composition, strength and broader daily function separate.

Does a positive antibody trial validate a peptide stack?

No. The tested molecule, comparator, population and background treatment define what the result supports. A different product needs its own evidence.

What result would change our view?

A reproducible improvement in meaningful function, supported by body-composition findings and an acceptable safety profile in the actual combination. A neutral or harmful result would be equally important for deciding where research should go next.

References

On November 19, 2026, we rechecked the resistance-exercise abstract and indexed results/methods passages, the BELIEVE, COURAGE and retatrutide abstracts, and EMBRAZE results. The resistance-exercise paper labels the same interval differently in its abstract versus main text, as noted above. These selected checks did not include complete trial supplements or individual-level datasets; earlier source-access limits remain applicable.